Roth Capital Still Sees 51% Upside For Sarepta’s Stock
October 1, 2014 2:29 PM EDT by Editor Corey Williams in Exclusively Published, Healthcare
In a research report issued yesterday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT) with a $34 price target, which represents a potential upside of 51% from where the stock is currently trading.
Chattopadhyay said, “SRPT’s investigational influenza compound (AVI-7100) has moved to multiple ascending dose testing in healthy volunteers. Importantly, AVI-7100 is based on SRPT’s advanced PMOplus platform, which could lead to lower dose and better COGS compared to the parent PMO chemistry. However, our short-term focus is on the initiation of patient dosing in the DMD pivotal study , hopefully prior to 3Q14 corporate update in November.”
as per a tweet
Skyworks weakness a buying opportunity, says Craig-Hallum
Craig-Hallum views the sell-off in Buy rated Skyworks as overdone and would buy shares aggressively on weakness. The analyst continues to expect Skyworks to report another good quarter and for shares to work higher.
I know no one cares
Ebola drug trials to be fast tracked in Africa • 7:25 AM
Douglas W. House, SA News Ed...
The Wellcome Trust, a global health charity, announces a ₤3.2M ($5.25M) grant to fund clinical trials in West Africa for several experimental Ebola drugs, including products from Mapp Biopharmaceutical, Serepta Therapeutics (NASDAQ:SRPT) and Tekmira (NASDAQ:TKMR).
The charity's Director, Jeremy Farrar says, "It's a huge challenge to carry out clinical trials under such difficult conditions, but ultimately this is the only way we will ever find out whether any new Ebola treatments actually work."
In August, a WHO panel of experts unanimously agreed that the circumstances are exceptional and it would be ethical to deploy and test unregistered experimental treatments in an effort to help people stricken with Ebola infection.
He mentioned the delays so this is nothing new
Many people are selling stocks, particularly small cap bios, to buy in. I believe this downward move will be short lived but do not discount the influence this IPO is having on many stocks. I heard someone say it sucked about $1 billion from the small biotech market. Also, I believe option expiration is having an affect on the market.
The investment firm sets a $17 price target on shares
I know there is no one on this board so I am really just talking to myself
Correct greyzone. Remember, GSK completely gave up on Prosensa's program. Given the lack of effective drugs on the market and, one would think the somewhat low barrier to get approval given the severity of the disease, GSK must have really thought very little of prosensa's drug and its commercial viability.
Dirk Haussecker @RNAiAnalyst 2m
$RNA truly doubt that re-dosing decision in best interest of patients.
Dirk Haussecker @RNAiAnalyst 1m
$RNA needs new chemistries; patients should switch to $SRPT treatment; at least chance here that it is meaningful.
I know no one is really on this board but I figured i would post it anyway
Clearly you haven't read about their recent acquisition. It's transformative. Future guidance was dramatically revised higher. Instead of relying on outdated yahoo numbers, do a little more DD before making such a comment. The future is extremely bright for this company. Listen to some of their more recent presentations
As most longs know, the group of children SRPT included in their trial were older, as was the company's intent. This was smart because as we know, DMD is a progressive disease so working with older children really makes these accomplishments even more spectacular. It's always been my belief, and i am sure many share the same belief, that if the drug is given early enough to these children, before any real muscle deterioration occurs, we really could see some amazing results. Perhaps not a cure but the progression of the disease could be slowed down substantially more than what we are seeing today. This is why it's so important to get this drug approved now before these children lose any more muscle function. Think of it in simplistic terms. You are diagnosed with cancer. Would treatment be more effective early on or if you waited years later?
will begin dosing of 2nd exon skipping drug in EU in near-term
Adam Feuerstein @adamfeuerstein 2m
Check that, some of you now know CG wasn’t lying. Others (me included) believed him all along. $SRPT
binarypharmer @binarypharmer Protected Tweets 8m
Oh #$%$ CG was speaking the truth this entire time.